Antisense technology and prospects for therapy of viral infections and cancer

Molecular Medicine Today

Volumn 3, Issue 1, 1997, Pages 31-38

  Wagner, R W ^a   Flanagan, W M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE;

CANCER THERAPY; CYTOMEGALOVIRUS; DNA MODIFICATION; EVOLUTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HYDROGEN BOND; REVIEW; RNA SEQUENCE; TARGET CELL; TECHNOLOGY; VIRUS INFECTION; WART VIRUS;

EID: 0031426571     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(96)10053-8     Document Type: Review

References (36)

1. Crooke S.T. Pharmacokinetic properties of several novel oligonucleotide analogs in mice J. Pharmacol. Exp. Ther. 277 1996 923 937
2. Bennett C.F. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides Mol. Pharmacol. 41 1992 1023 1033
3. Wagner R.W. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines Science 260 1993 1510 1513
4. Flanagan W.M. Su L.L. Wagner R.W. Elucidation of gene function using C-5 propyne antisense oligonucleotides Nat. Biotechnol. 14 1996 1139 1145
5. Bergan R. Connell Y Fahmy B. Neckers L. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy Nucleic Acids Res. 21 1993 3567 3573
6. McKay R. Dean M.N. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate Proc. Natl. Acad. Sci. U. S. A. 91 1994 1762 1766
7. Monia B.P. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-Raf kinase Nat. Med. 2 1996 668 675
8. Plenat F. Animal models of antisense oligonucleotides: lessons for use in humans Mol. Med. Today 2 1996 250 257
9. (Suppl.) Matteucci M.D. Wagner R.W. In pursuit of antisense Nature 384 1996 20 22
10. Stein C.A. Does antisense exist? Nat. Med. 1 1995 1119 1121
11. Lisziewicz J. Antisense oligodeoxynucleotide phosphorothioate complementary to gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells Proc. Natl. Acad. Sci. U. S. A. 91 1994 7942 7949
12. Matsukura M. Phosphorothioate analogs of oligodeoxynu-cleotides: inhibitors of replication and cytopathic effects of human immuno-deficiency virus Proc. Natl. Acad. Sci. U. S. A. 84 1987 7706 7710
13. Lisziewicz J. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates Proc. Natl. Acad. Sci. U. S. A. 90 1993 3860 3864
14. Milligan J.F. Matteucci M.D. Martin J.C. Current concepts in antisense drug design J. Med. Chem. 36 1993 1923 1937
15. Agrawal S. Temsamani J. Galbraith W. Tang J. Pharmacokinetics of antisense oligonucleotides Clin. Pharmacokinet. 28 1995 7 16
16. Galbraith W.M. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey Antisense Res. Dev. 4 1994 201 206
17. Zhang R. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM91) in HIV-infected subjects Clin. Pharmacol. Ther. 58 1995 44 53
18. Azad R.F. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region Antimicrob. Agents Chemother. 37 1993 1945 1954
19. Hutcherson S.L. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients Proceedings of the 35th International Conference on Antimicrobial Agents and Chemotherapy San Francisco, CA, USA 1995 American Society for Microbiology 204
20. Cowsert L.M. Fox M.C. Zon G. Mirabelli C.K. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts Antimicrob. Agents Chemother. 37 1993 171 177
21. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats J. Pharm. Exp. Ther. 269 1994 89 94
22. Tonkinson J.L. Stein C.A. Antisense oligodeoxynucleotides as clinical therapeutic agents Cancer Invest. 14 1996 54 65
23. Stein C.A. Phosphorothioate antisense oligonucleotides: questions of specificity Trends Biotechnol. 14 1996 147 149
24. Krieg A.M. CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
25. Stein C.A. Krieg A.M. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides Antisense Res. Dev. 4 1994 67 69
26. Heidenreich O. Kang S-H. Xu X. Nerenberg M. Application of antisense technology to therapeutics Mol. Med. Today 1 1995 128 133
27. Flanagan W.M. Kothavale A. Wagner R.W. Effects of oligonu-cleotide length, mismatches, and mRNA levels on C-5 propyne-modified anti-sense potency Nucleic Acids Res. 24 1996 2936 2941
28. Monia B.P. Selective inhibition of mutant Ha- ras mRNA expression by antisense oligonucleotides J. Biol. Chem. 267 1992 19954 19962
29. Bennett C.F. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides J. Immunol. 152 1994 3530 3540
30. White E. Life, death, and the pursuit of apoptosis Genes Dev. 10 1996 1 15
31. Oltvai Z.N. Milliman C.L. Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death Cell 74 1993 609 619
32. Arnold L.J. High affinity antisense oligonucleotides and their application to disease targets Oligonucleotide-and Gene Therapy-based Antisense Therapeutics, International Business Communications San Diego, CA, USA 1996 International Business Communications 1 22
33. Dean N.M. McKay R. Condon T.P. Bennett C.F. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters J. Biol. Chem. 269 1994 16416 16424
34. Dean N. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression Cancer Res. 56 1996 3499 3507
35. McKay R.A. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase-α by the incorporation of 2′- O -propyl modifications Nucleic Acids Res. 24 1996 411 417
36. Altmann K.H. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals Chemia 50 1996 168 176